{"id":"W2168579528","doi":"10.1016/s1470-2045(13)70154-2","title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":654,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"National Institutes of Health; Institute of Cancer Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; F. Hoffmann-La Roche","keywords":"Capecitabine; Medicine; Bevacizumab; Internal medicine; Irinotecan; Colorectal cancer; Hazard ratio; Clinical endpoint; Oxaliplatin; Adverse effect; Oncology; Population; Cancer; Randomized controlled trial; Chemotherapy; Surgery; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152707,0.001737979,0.00262498,0.0003919885,0.0003949429,0.0009971159,0.0006356621,0.001538756,0.006505406],"category_scores_gemma":[0.001790587,0.0006149008,0.002188496,0.0003968919,0.001014453,0.001265325,0.0004075591,0.002771995,0.0007569253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008550219,"about_ca_system_score_gemma":0.0007828015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001618506,"about_ca_topic_score_gemma":0.004222525,"domain_scores_codex":[0.9995677,0.0002239782,0.0000259264,0.00008095763,0.00002617151,0.00007515049],"domain_scores_gemma":[0.9991174,0.0003064544,0.0001811001,0.00004976886,0.00004017986,0.0003050233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9835082,0.002509728,0.0004421093,0.0004045436,0.0007200863,0.00003274549,0.00005028089,0.0002631286,0.001277922,0.00007914792,0.0005701993,0.01014191],"study_design_scores_gemma":[0.9383504,0.05860614,0.00163392,0.00003100938,0.000369788,0.00003104717,0.00002552666,0.0002748515,0.0001430221,0.0001139025,0.0004080393,0.00001220268],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894263,0.005305968,0.0003718802,0.0006938377,0.0005516729,0.001373427,0.0006956541,0.00006273994,0.001518626],"genre_scores_gemma":[0.9880897,0.003416398,0.001098911,0.0009799361,0.0004954064,0.001534993,0.0009638966,0.00001792814,0.003402679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006505406,"threshold_uncertainty_score":0.02176273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06574882485102473,"score_gpt":0.374869717678169,"score_spread":0.3091208928271442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}